Platinum-Chromium Stent Advances Coronary Disease Treatment

The REBEL Platinum Chromium (PtCr) Coronary Stent System is based on a proprietary PtCr alloy and a customized stent architecture design. The system features high visibility, low recoil, excellent radial strength and fracture resistance, while at the same time improving axial strength and deliverability. The stent is laser cut into a pattern which consists of serpentine rings connected by links that are polished to a uniform rounded surface. The REBEL PtCr stent is available premounted on the rapid exchange Monorail or on an over-the-wire delivery catheter.

The enhanced low-profile Monorail delivery system features a shorter, more visible tip, a dual-layer balloon, and a bi-segment inner lumen designed to facilitate precise stent delivery across challenging lesions. The REBEL Stent is the same design as the Promus Premier Stent, but without the Everolimus drug-eluting stent (DES) component, and is offered in a matrix of 46 sizes, ranging in diameter from 2.25–4.50 mm, and lengths of 8–32 mm. The REBEL PtCr stent is a product of Boston Scientific (Natick, MA, USA), and has been approved by the US Food and Drug Administration.

“Boston Scientific is committed to developing the best treatment options for all patients with coronary artery disease,” said Kevin Ballinger, president of interventional cardiology at Boston Scientific. “Launching the Rebel Stent System in the US is another important step to ensure that we offer physicians the most differentiated and broadest product portfolio possible.”

“Bare-metal stents are an important part of our practice, as not every patient can receive a drug-eluting stent. This new bare-metal stent has the same great visibility and deliverability as the PREMIER DES, but allows me to treat patients who are not candidates for DES therapy,” said John Wang, MD, of Medstar Union Memorial Hospital (Baltimore, MD, USA). “In addition, the platinum chromium architecture provides great radial strength with low recoil, which is particularly important in patients receiving bare-metal stents.”

Related Links:
Boston Scientific